Physician profile
David Timothy Powell
NPI 1639499197
$3,045.46
in general payments reported to CMS, 2019-2025
46 companies · $937 in 2025
The $937 reported for 2025 was more than what a typical Neuroradiology provider received nationally (typical 2025 total: $278).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $41.77 · 2022: $240 · 2023: $260 · 2024: $1,567 · 2025: $937.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,764.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,764.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $385.43 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $205.85 | 2022-2025 | Tagrisso, Calquence, Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $205.42 | 2020-2025 | Alunbrig, Ninlaro, Fruzaqla |
| Lilly USA, LLC | $152.70 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Genentech USA, INC. | $145.68 | 2022-2025 | Tecentriq, Perjeta, Itovebi |
| Incyte Corporation | $135.13 | 2020-2025 | Monjuvi, Pemazyre, Jakafi |
| Aveo Pharmaceuticals, INC. | $124.40 | 2024-2025 | |
| Abbvie INC. | $107.95 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $96.21 | 2022-2024 | |
| Servier Pharmaceuticals LLC | $94.97 | 2022-2025 | |
| Karyopharm Therapeutics INC. | $94.41 | 2022-2025 | Xpovio |
| Daiichi Sankyo INC. | $84.25 | 2024-2025 | Enhertu |
| Jazz Pharmaceuticals INC. | $81.18 | 2024-2025 | |
| Sobi, INC | $76.55 | 2024-2025 | |
| Eisai INC. | $68.44 | 2024-2025 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $60.81 | 2024 | Erleada, Rybrevant |
| Spectrum Pharmaceuticals INC. | $59.99 | 2024-2025 | Rolvedon |
| Adc Therapeutics America, INC. | $58.75 | 2024-2025 | |
| Taiho Oncology, INC. | $58.19 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.80 | 2024-2025 | Gilotrif |
| Pharmaessentia USA Corporation | $52.53 | 2024 | Besremi |
| Immunocore Limited | $50.20 | 2024-2025 | Kimmtrak |
| Pfizer INC. | $46.63 | 2024 | |
| Puma Biotechnology, INC. | $37.64 | 2024-2025 | |
| Emd Serono, INC. | $36.86 | 2023 | Tepmetko |
| Seagen INC. | $35.98 | 2022-2023 | Adcetris |
| Beigene USA, INC. | $35.53 | 2024 | Brukinsa |
| Novartis Pharmaceuticals Corporation | $33.67 | 2024 | |
| Genzyme Corporation | $32.85 | 2024 | |
| Genmab U.S., INC. | $29.06 | 2024 | Tivdak |
| Macrogenics, INC. | $28.75 | 2023 | |
| Alexion Pharmaceuticals, INC. | $28.71 | 2024 | Ultomiris |
| Genentech, INC. | $25.79 | 2024 | Columvi, Lunsumio |
| Geron Corporation | $23.62 | 2025 | Rytelo |
| Novocure INC. | $22.74 | 2025 | Optune Lua (Novottf-200t) |
| Glaxosmithkline, LLC. | $20.25 | 2024 | Ojjaara |
| Verastem, INC. | $19.77 | 2025 | Avmapki Fakzynja Co-Pack |
| Kyowa Kirin, INC. | $18.03 | 2024 | Poteligeo |
| Sumitomo Pharma America, INC. | $15.55 | 2025 | Orgovyx |
| Exelixis INC. | $15.38 | 2025 | Cabometyx |
| Janssen Pharmaceuticals, INC | $15.14 | 2023 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $14.79 | 2024 | Libtayo |
| Coherus Oncology, INC. | $14.32 | 2025 | Loqtorzi |
| Springworks Therapeutics, INC. | $14.18 | 2024 | Ogsiveo |
| Helsinn Therapeutics (U.S.), INC. | $13.68 | 2022 | |
| Advanced Accelerator Applications | $10.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.